Singapore (Press Release) – KYAN Thera­peutics, Inc. ("KYAN"), a frontier bio­tech com­pany with a novel drug-dose com­bi­na­tion op­ti­miz­ing plat­form, Optim.AI, has entered into an ex­clu­sive li­cense agree­ment with Georgetown Uni­ver­sity for novel sel­ective Class II HDAC in­hib­i­tors. KYAN has already com­menced pre­clin­i­cal de­vel­op­ment of the lead can­di­date, which has been designated as KYAN-001, with early pos­i­tive re­­sults.

In vitro and in vivo stud­ies of KYAN-001 have shown high ef­fi­cacy for Multiple Myeloma and Prostate Cancer. The low toxicity and metabolic stability of KYAN-001 in­di­cates a better safety and tol­er­a­bil­ity profile than FDA ap­prov­ed …